Genfleet Therapeutics (shanghai) Inc.
Clinical trials sponsored by Genfleet Therapeutics (shanghai) Inc., explained in plain language.
-
New hope for hard-to-treat lung cancer: targeted drug combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called GFH375, alone or with other medicines, in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. About 90 participants will be split into three groups to see which treatment works best and is safe. The goal is to…
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 26, 2026 09:27 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug enters final testing phase
Disease control Not yet recruitingThis study tests a new drug, GFH375, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants must have already tried at least one standard treatment. The goal is to see if GFH375 works better than standard chemotherapy at contr…
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests a new drug called GFH276 in people with advanced cancers that have RAS mutations, including pancreatic, lung, and colorectal cancers. The goal is to see if the drug is safe and can shrink tumors or slow disease. About 450 adults aged 18-75 will take part in two p…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 19, 2026 11:48 UTC